Categories
Featured Health Care Stocks Investing Stock Market Today Stocks to Watch

Top Stocks To Buy Now? 3 Health Care Stocks To Know

Looking for defensive plays amid the market uncertainty? These health care stocks are making waves.

For investors navigating the stock market today, health care stocks would still be in fashion. Namely, the industry remains as vital to the general population as ever. Throughout the current pandemic, many names in the space have and continue to make massive strides in the operations. This would be the case from vaccine companies like Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) to retail pharmacy names like CVS Health (NYSE: CVS).

On one hand, the leading names in the coronavirus vaccine race are reported looking to expand the possible applications of their vaccine. Namely, Pfizer and BioNTech are reportedly on track to apply for FDA approval for their vaccine to be used in children 5 and older. Through an interview with the New York Times last week, Dr. Ozlem Tureci, co-founder of BioNTech, revealed the details. According to Dr. Tureci, results from trials involving children 5 to 11 years old will be released in a matter of weeks. On the other hand, CVS opened its first MinuteClinic locations in Washington. These walk-in medical clinics inside CVS Pharmacy stores provide a wide array of health care services.

On top of all this, President Joe Biden’s recent workplace vaccine mandates would continue to highlight the industry. In detail, the Department of Labor is planning to declare an emergency rule targeting all employers with over 100 employees. Said employers will have to ensure that all workers are fully vaccinated or tested at least once a week. With all that said, could one of these top health care stocks be worth your attention this week?

Top Health Care Stocks To Buy [Or Sell] This Week

Moderna Inc.

To begin, we have Moderna, a biotech company that utilizes messenger RNA (mRNA) science to treat a broad spectrum of diseases across six modalities. A modality is a family of potential mRNA medicines that are consistent in both design and how and where they are delivered in the body. This would include cancer vaccines and prophylactic vaccines. The company is on track to deliver up to 1 billion doses of its coronavirus vaccine in this financial year.

With that being said, MRNA stock currently trades at $435.37 as of 10:56 a.m. ET and has increased by over 570% in the past year alone. Last week, it announced that National Resilience is seeking to build a manufacturing ecosystem to manufacture mRNA for Moderna’s coronavirus vaccine. Under the terms of the multi-year agreement, Resilience will produce mRNA at its facility in Ontario, Canada to manufacture Moderna’s vaccine for distribution worldwide.

It seems to be a busy month for the company as it also submitted data to the European Medicines Agency (EMA) for its coronavirus vaccine booster on September 3, 2021. This submission will be for conditional marketing approval (CMA) with the EMA. “We are pleased to submit for a conditional marketing approval with the EMA for our booster candidate at the 50 µg dose level. The amended Phase 2 study and additional analyses shows that a 50 µg booster dose of our COVID-19 vaccine induces robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We remain committed to staying ahead of the virus and following the evolving epidemiology of SARS-CoV-2.” Given this piece of news, will you consider buying MRNA stock?

Source: TD Ameritrade TOS

Read More

Clover Health Investments Corp.

Next up, we have Clover Health, a health care company that operates as a next-generation Medicare Advantage insurer. In essence, the company leverages its flagship software platform, the Clover Assistant to provide seniors with highly affordable health care plans. It also allows physicians to make data-driven decisions with personalized insights to improve outcomes. CLOV stock currently trades at $8.44 as of 10:56 a.m. ET.

On September 8, 2021, the company announced a partnership with athenahealth through the company’s Marketplace program. Furthermore, as part of the athenahealth Marketplace, the Clover Assistant application will be available to Clover-contracted physicians in athenahealth’s growing network of healthcare providers to offer them clinical decision support, without requiring a transition to risk-based contracts. This seamless access to innovative models of data-driven care could benefit the company in the long run.

Last month, it also reported impressive financials. Notably, its total revenue for the quarter increased by 140% year-over-year to $412 million. The company also says that lives under the Clover Management nearly doubled from the first quarter to approximately 129,000. Also, the company is on track to managing over $1 billion of annualized revenue. For these reasons, will you be adding CLOV stock to your portfolio?

Source: TD Ameritrade TOS

[Read More] Top Reddit Stocks To Buy Right Now? 5 For Your Late 2021 Watchlist

Tilray Inc.

Tilray is the last on our list today. Sure, most may not immediately think of TLRY stock when considering the top health care stocks in the stock market. However, the case for medical marijuana users across the globe continues to build regardless. With Tilray being one of the largest cannabis companies globally in terms of revenue, it is no newcomer to the medical weed market. For a sense of scale, Tilray’s operations span across the U.S., Canada, Europe, Australia, and Latin America.

Now, TLRY stock trades at $12.06 as of 10:57 a.m. ET. This would be after gaining by 120% in the past year. With both rising consumer demand and legislative momentum behind the U.S. industry now, TLRY stock could be worth watching. If anything, the company does not appear to be slowing down anytime soon. As of last week, Tilray received stockholder approval to increase its authorized shares.

According to CEO Irwin Simon, this move will serve to help Tilray further build on its strong momentum so far. Since its merger with fellow marijuana industry giant Aphria back in May, the company has made numerous significant plays. This includes the launch of a new medical brand in Canada and acquiring a majority stake in MedMen Enterprises. The latter of which would provide Tilray with a quick entry into the U.S. market should federal legalization take hold. Given all of this, would you consider TLRY stock a buy now?

Source: TD Ameritrade TOS

By Josh Dylan

Josh Dylan is an active contributor to StockMarket.com. His forte is in geosocial events and emerging trends in the stock market today. As an active contributor to other financial outlets like MarijuanaStocks.com, his ability to study current events and determine the potential market reaction is what sets him apart from other writers.

After studying at UC Santa Cruz and earning a bachelor's of art and art history, Josh also went on to start his own business in art resale. Identifying underserved niches like this has allowed him to think outside the box when it comes to applying this approach to the stock market.

His new-age take on social media and branding gave Josh the foresight to apply certain lifestyle trends to market moving topics. This has included the recent trend in the cannabis industry and marijuana stocks as well as following emerging technology such as artificial learning and web-bots. Fundamentals are just as important as momentum in Josh’s opinion. Being able to understand how to apply popular trends to investing is of major importance. If the price of oil is sinking but the price of gold is following along, we want to understand why, not just follow the broader trend.

Josh Dylan makes it a point to not only mention what hot “today” but also find ways to apply that to find future opportunity in the stock market. What’s more is that Josh has become an active part in the StockMarket.com social media team. He works to delivery top research not only one StockMarket.com but also bring it to the readers, directly.

By studying the macro-economic events in the market, Josh makes sure to find events that could shift micro-economic trends. He prides himself on taking a unique approach to information but not taking things for “face value”. When it comes to the stock market, things can change at a moment’s notice and Josh makes sure to stay ahead of that with sound research and diligence. When Josh isn’t writing about the stock market, he enjoys spending time with his family and surfing. He currently calls Southern California his home.

View Archive
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments